about
Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBromelain as a Treatment for Osteoarthritis: a Review of Clinical StudiesNon-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic PericarditisBalancing the cyclooxygenase portfolioEffects of single-dose injectable paracetamolversus propacetamol in pain management after minor gynecologic surgery: A multicenter, randomized, double-blind, active-controlled, two-parallel-group study.Coxib medications to be handled with care.Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical studyMyocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis.What influences seniors' choice of medications for osteoarthritis? Qualitative inquiry.A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee.The eicosanoid cascade: possible role in gliomas and meningiomas.Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national surveyNitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trialsCOX-2 inhibitors and the heart: are all coxibs the same?A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee.Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.Efficacy of a natural mineral complex in North American adults with osteoarthritis of the knee: a randomized double-blind placebo-controlled study.Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety.In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines.Why don't we initiate more large simple randomized controlled trials?In Vivo Osteoinduction: Evaluating 2-Beta Coxatene as an Immunoinductive Compound and Novel Ingredient for Joint Support.Seeking disclosure.COX-2 inhibitors and type 4 error.Scheduled Intravenous Acetaminophen Improves Patient Satisfaction With Postcraniotomy Pain Management: A Prospective, Randomized, Placebo-controlled, Double-blind Study.Seeking disclosure.Can oliceridine (TRV130), an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator, provide analgesia without opioid-related adverse reactions?The inverse benefit law: how drug marketing undermines patient safety and public health.
P2860
Q24555478-92E711D8-632D-4E77-A62A-2A6218CD6A03Q24558705-82A379AF-919A-46BE-865D-EFF1CB41E153Q26749687-B8831696-EDD3-47E7-B8B9-EA5B166E19EEQ28218310-59E16A68-0C55-4554-99E7-2E023D62AEA9Q33737649-9B554880-8673-41D5-949F-32D9F7D05E59Q33759261-B529C50E-4CA6-400D-84CE-1A4B578AC346Q34165468-C19641A9-69E9-4F31-A00C-523CE194B121Q34280379-6464561A-1EAA-4ACD-A07B-AE470FFC943EQ34589334-06FDE855-F8A0-4879-B1D9-D118F90E6857Q34683736-257A66FE-242B-47BC-AE29-C3B0857AF680Q35407746-48CF9D8D-C467-4E03-AAC3-8813B953E99BQ35615457-5CB132F6-5C5E-4CAE-A36A-84B1C0BA2600Q35688266-BE517A05-BE51-4026-953A-30076E4F6DC6Q35848746-5D570DC5-8B12-45EF-9E37-3ED663F6DDE4Q35961855-116B4FBD-A7B9-464C-87AE-A381EF84A610Q36441763-94F2611F-7DFA-4C20-886B-9E3C43D535B5Q36955387-BD090B50-79AF-4EA5-8BBD-D8A7147DA93EQ37061561-B9CEC3F0-5EB8-464B-83A3-003201A40682Q37301182-B34C7A79-3D95-45C2-880D-51B81A4613F9Q37900831-8ACDA701-A102-42DE-A6B2-ACB156ACE539Q39089408-6074D51B-C6FB-439C-A0A1-93793655011CQ40184744-02D9D12C-1A54-43E8-95F9-3BAAA094E5B7Q41644553-69C82D4B-EFE8-4CC4-B74C-0F995FA249EAQ42859844-F8F7CCD0-C857-42A4-BA2F-04402528F5C1Q42905098-25B1F741-ECDE-47A0-BF9F-216A68BF8DEEQ47979623-20AC7A02-FCDE-4ABC-A8EA-24A5420A167EQ50425500-DF0103B4-DA7B-4FEE-9EDA-18D3BF562C74Q52568263-00D847B6-589E-4341-8CF6-524474132789Q53054239-22F3DEDC-B57C-45E6-ADE6-EF675455F30B
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
The double-edged sword of COX-2 selective NSAIDs
@ast
The double-edged sword of COX-2 selective NSAIDs
@en
The double-edged sword of COX-2 selective NSAIDs
@nl
type
label
The double-edged sword of COX-2 selective NSAIDs
@ast
The double-edged sword of COX-2 selective NSAIDs
@en
The double-edged sword of COX-2 selective NSAIDs
@nl
prefLabel
The double-edged sword of COX-2 selective NSAIDs
@ast
The double-edged sword of COX-2 selective NSAIDs
@en
The double-edged sword of COX-2 selective NSAIDs
@nl
P2860
P1476
The double-edged sword of COX-2 selective NSAIDs
@en
P2093
James M Wright
P2860
P304
P407
P577
2002-11-01T00:00:00Z